We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$891M
Cap. Flow
-$92.8M
Cap. Flow %
-0.89%
Top 10 Hldgs %
36.27%
Holding
147
New
14
Increased
53
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$98.5M
2
SIEN
Sientra, Inc.
SIEN
+$54.3M
3
GILD icon
Gilead Sciences
GILD
+$50.4M
4
MGLN
Magellan Health Services, Inc.
MGLN
+$47.6M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$42.9M

Top Sells

Rank Stock Value
1
CFN
CAREFUSION CORPORATION
CFN
+$215M
2
A icon
Agilent Technologies
A
+$79M
3
ARWR icon
Arrowhead Research
ARWR
+$76.5M
4
STJ
St Jude Medical
STJ
+$54.8M
5
QGENF
QIAGEN NV
QGENF
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.82%
2 Financials 0.08%
3 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$324B
$166M 1.58%
3,055,234
+265,458
+10% +$14.8M
REGN icon
27
Regeneron Pharmaceuticals
REGN
$73.1B
$160M 1.53%
390,200
+20,600
+6% +$8.1M
AGN
28
DELISTED
Allergan Inc
AGN
$158M 1.51%
741,300
-156,400
-17% -$31.1M
MCK icon
29
McKesson
MCK
$105B
$154M 1.47%
742,000
+34,000
+5% +$6.91M
ZBH icon
30
Zimmer Biomet
ZBH
$18.7B
$145M 1.39%
1,321,181
+23,690
+2% +$2.5M
NBIX icon
31
Neurocrine Biosciences
NBIX
$18.2B
$133M 1.27%
5,968,600
+175,000
+3% +$3.32M
TRNX
32
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$123M 1.17%
4,805,000
– –
NPSP
33
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$106M 1.01%
2,954,900
+338,900
+13% +$10.1M
SYK icon
34
Stryker
SYK
$134B
$97.3M 0.93%
1,031,600
+29,000
+3% +$2.57M
PODD icon
35
Insulet
PODD
$11.7B
$92M 0.88%
1,997,000
+44,000
+2% +$1.88M
PFE icon
36
Pfizer
PFE
$144B
$85.9M 0.82%
2,907,986
+93,806
+3% +$2.69M
INFI
37
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$80M 0.76%
4,736,900
– –
OTIC
38
DELISTED
Otonomy, Inc.
OTIC
$75.2M 0.72%
2,256,398
– –
MGLN
39
DELISTED
Magellan Health Services, Inc.
MGLN
$72.5M 0.69%
1,208,000
+805,400
+200% +$47.6M
LAB icon
40
Standard BioTools
LAB
$317M
$72.1M 0.69%
2,136,200
+36,000
+2% +$1.02M
WMGI
41
DELISTED
Wright Medical Group Inc
WMGI
$67.9M 0.65%
2,527,000
+83,000
+3% +$2.43M
AFFX
42
DELISTED
Affymetrix Inc
AFFX
$64.8M 0.62%
6,568,000
– –
ALXN
43
DELISTED
Alexion Pharmaceuticals
ALXN
$61.4M 0.59%
332,000
+20,000
+6% +$3.71M
MNK
44
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$56.1M 0.54%
567,001
+273,000
+93% +$25.1M
SIEN
45
DELISTED
Sientra, Inc.
SIEN
$53.5M 0.51%
+318,531
New +$54.3M
AGN
46
CALL
DELISTED
Allergan Inc
AGN
$53.1M 0.51%
+250,000
New +$49.7M
INSY
47
DELISTED
Insys Therapeutics, Inc.
INSY
$52.4M 0.5%
2,486,400
+1,015,200
+69% +$20.1M
JNJ icon
48
Johnson & Johnson
JNJ
$643B
$51.8M 0.49%
495,000
+72,000
+17% +$7.59M
NUVA
49
DELISTED
NuVasive, Inc.
NUVA
$50.6M 0.48%
1,072,000
+410,000
+62% +$17.1M
TSRO
50
DELISTED
TESARO, Inc.
TSRO
$49.5M 0.47%
+1,330,000
New +$41M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2014 Portfolio in Review

As of Q4 2014, OrbiMed held 147 positions worth $10.5B, up 9.3% from $9.57B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed's Q4 2014 filing shows 14 new, 53 increased, 21 reduced and 16 closed positions. Its largest new stake was Sientra, Inc.: 318,531 shares worth $53.5M. The largest sale was CAREFUSION CORPORATION, an estimated $215M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2014 buy was Sientra, Inc.: 318,531 shares worth $53.5M.
  • OrbiMed added most to Biogen in Q4 2014, an estimated $98.5M increase.
  • OrbiMed's biggest Q4 2014 reduction was Agilent Technologies, cutting an estimated $79M.
  • OrbiMed fully exited CAREFUSION CORPORATION in Q4 2014, selling an estimated $215M.
  • OrbiMed's ten largest holdings make up 36% of its $10.5B portfolio in Q4 2014.
  • OrbiMed opened 14 new positions and closed 16 in Q4 2014.
  • OrbiMed's portfolio value rose 9.3% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.